9]; 128: Available from: 8. Viollet B, Guigas B, Garcua NZ, Leclerc J, Foretz M,

(1)

DAFTAR PUSTAKA

1. Filho HGL, Ferreira NL, de Sousa RB, de Carvalho ER, Lobo PLD, Filho JGL. Experimental model of myocardial infarction induced by isoproterenol in rats. Rev Bras Cir Cardiovasc [Internet]. 2011 [cited 2014 Feb 9];

26(3):469-76. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/22086586

2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD.

Third universal definition of myocardial infarction. Eur Heart J [Internet].

2012 [cited 2014 Feb 9]; 33:2551-2567. Available from:

http://www.escardio.org/guidelines-surveys/esc-

guidelines/GuidelinesDocuments/Guidelines_Univ_Def_Myocardial_Infarc_

FT.pdf

3. Zafari AM. Myocardial infarction [Internet]. New York: Medscape; date unknown [updated 2014 Jan 21; cited 2014 Feb 9]. Available from:

http://emedicine.medscape.com/article/155919-overview#a0156

4. Cardiac remodeling: basic aspects [Internet]. Philadelphia (USA): Wolters Kluwer Health; date unknown [updated 2012 Apr 9; cited 2014 Feb 8].

Available from: http://www.uptodate.com/contents/cardiac-remodeling-basic- aspects

5. McMurray JJV. Systolic heart failure. N Engl J Med [Internet]. 2010 [cited 2014 Feb 21]; 362:228-38. Available from:

http://www.nejm.org/doi/pdf/10.1056/NEJMcp0909392

6. Watson K, Summers KM. Depression in patients with heart failure: clinical implications and management. Pharmacotherapy [Internet]. 2009 [cited 2014 Feb 9]; 29(1):49-63. Available from:

7. Yancy CW, Jessup M, Bozkurt B, Buttler J, Casey DE, Drazner Jr.MH, et al.

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation [Internet]. 2013 [cited 2014 Feb

(2)

9]; 128:240-327. Available from:

https://circ.ahajournals.org/content/128/16/e240.extract

8. Viollet B, Guigas B, Garcua NZ, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) [Internet]. 2012 [cited 2014 Feb 10]; 122(6):253-270. Available from:

9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care

[Internet]. 2009 [cited 2014 Feb 10]; 32(1):193-203. Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606813/

10. Soraya H, Khorrami A, Garjani A, Maleki-Dizaji N, Garjani A. Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacol Rep [Internet]. 2012 [cited 2014 Feb 10]; 64:1476-1484. Available from:

11. Fu Y, Xiao H, Ma X, Jiang S, Xu M, Zhang Y. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation. Acta Pharmacol Sin [Internet]. 2011 [cited 2014 Feb 17]; 32:879-887. Available from:

12. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1-Smad3 signalling pathway.

Cardiovasc Res [Internet]. 2010 [cited 2014 Feb 13]; 87(3):504-513.

Available from: http://www.ncbi.nlm.nih.gov/pubmed/20200042

13. Yin M, van der Horst ICC, van Melle JP, Qian C, van Glist WH, Sillje HHW, et al. Metformin improves cardiac function in a nondiabetic rat model of post- MI heart failure. Am J Physiol Heart Circ Physiol [Internet]. 2011 [cited 2014 Feb 13]; 301:H549-H468. Available from:

14. Cha HN, Choi JH, Kim YW, Kim JY, Ahn MW, Park ST. Metformin inhibits isoproterenol-induced cardiac hypertrophy in mice. Korean J Physiol

(3)

Pharmacol [Internet]. 2010 [cited 2014 Feb 13]; 14:377-384. Available from:

15. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, e al.

Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res [Internet]. 2009 [cited 2014 Feb 17]; 104:403-411. Available from:

16. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates. Comp Med [Internet]. 2009 [cited 2014 Feb 16]; 59(4):339-343. Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779208/

17. Upaganlawar A, Gandhi H, Balaraman R. Isoproterenol induced myocardial infarction: protective role of natural products. J Pharmacol Toxicol [Internet].

2011 [cited 2014 Feb 16]; 6(1):1-17. Available from:

http://docsdrive.com/pdfs/academicjournals/jpt/2011/1-17.pdf

18. Rahmatulla M, Devi KL. Origination and development of isoproterenol- induced myocardial infarction in male wistar rats. Int Res J Pharm [Internet].

2013 [cited 2014 Feb 16]; 4(5):26-35. Available from:

http://www.irjponline.com/admin/php/uploads/1776_pdf.pdf

19. Nakajima-Takenaka C, Zhang G, Obata K, Tohne K, Matsuyoshi H, Nagai Y, et al. Left ventricular function of isoproterenol-induced hypertrophied rat hearts perfused with blood: mechanical work and energetics. Am J Physiol Heart Circ Physiol [Internet]. 2009 [cited 2014 Feb 16]; 297:H1763-H1743.

Available from: http://ajpheart.physiology.org/content/297/5/H1736 20. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical

implications: a consensus paper from an international forum on cardiac remodeling. JACC [Internet]. 2000 [cited 2014 Feb 9]; 35(3):569-82.

Available from: http://www.ncbi.nlm.nih.gov/pubmed/10716457 21. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial

infarction pathophysiology and therapy. Circulation [Internet]. 2000 [cited

(4)

2014 Feb 15]; 101(25):2981-8. Available from:

22. Heidrich F, Schotola H, Popov AF, Sohns C, Schuenemann J, Friedrich M, et al. AMPK—activated protein kinase and its role in energy metabolism of the heart. Curr Cardiol Rev [Internet]. 2010 [cited 2014 Feb 17]; 6:337-342.

Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083815/

23. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol [Internet]. 2007 [cited 2014 Feb 23];

8(10):774-85. Available from:

24. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol [Internet]. 2007 [cited 2014 Feb 23]; 47:185-210.

25. Hue L, Rider MH. The AMP-activated protein kinase: more than an energy sensor. Essays Biochem [Internet]. 2007 [cited 2014 Feb 23]; 43:121-137.

26. Hou X, Song J, Li XN, Zhang L, Wang X, Chen L, et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun [Internet]. 2010 [cited 2014 Feb 23]; 396:199-205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20398632

27. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, et al.

Metformin prevents progression of heart failure in dogs: role of AMP- activated protein kinase. Circulation [Internet]. 2009 [cited 2014 Feb 17];

119:2568-2577. Available from:

http://circ.ahajournals.org/content/119/19/2568

28. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure.

Cardiovasc Res [Internet]. 2011 [cited 2014 Feb 17]; 90:224-233. Available from: http://cardiovascres.oxfordjournals.org/content/90/2/224.full.pdf

(5)

29. Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblast.

Biochem Biophys Res Common [Internet]. 2008 [cited 2014 Feb 24].

Available from: http://www.ncbi.nlm.nih.gov/pubmed/18243130.

30. Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother [Internet]. 2013 [cited 2014 Feb 7]; 4(4):303-306.

Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826013/?report=reader#!po=

46.8750

31. National Research Council of the National Academies. Guide for the care and use of laboratory animals. 8th ed [Internet]. Washington, D.C.: The National Academies Press; 2011 [cited 2014 Feb 7]. Available from:

http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory- animals.pdf.

32. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol [Internet]. 2008 [cited 2014 Mar 17];

60(1):63-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18088506 33. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic

cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos [Internet]. 2012 [cited 2014 Mar 17]; 40(6):1170-7. Available from:

34. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Furlong TJ, et al.

Clinical pharmacokinetics of metformin. Clin Pharmacokinet [Internet]. 2011 [cited 2014 Mar 17]; 50(2):81-98. Available from:

35. Liu L, Cui J, Yang Q, Jia C, Xiong M, Ning B, et al. Apocynin attenuates isoproterenol-induced myocardial injury and fibrinogenesis. Biochem Biophys Res Commun. 2014 [cited 2014 July 13].

(6)

36. AVMA guidelines for the euthanasia of animals: 2013 edition [Internet].

Schaumburg: American Veterinary Medical Association; 2013 [cited 2014 Feb 7]. Available from:

https://www.avma.org/kb/policies/documents/euthanasia.pdf

37. Heart dissection [Internet]. Oxford (UK): European Mouse Phenotyping Resource of Standardised Screens (EMPReSS); 2004 [cited 2014 Feb 8].

Available from:

http://www.mousebook.org/sops/020_001_heart_dissection_080407.pdf 38. Muntiha M. Teknik pembuatan preparat histopatologi dari jaringan hewan

dengan pewarnaan hematoksilin dan eosin (H&E). Temu Teknis Fungsional Non Peneliti [Internet]. 2001 [cited 2014 Feb 8]; 156-163. Available

from: http://balitnak.litbang.deptan.go.id/index.php?option=com_phocadown load&view=category&id=66:3&download=1043:3&start=20&Itemid=10.

39. Masson’s Trichrome stain [Internet]. Minneapolis (USA): Lillehei Heart Institute – Histology and Microscopy Research Facility; date unknown [cited 2014 Feb 8]. Available from:

http://www.med.umn.edu/lhi/prod/groups/med/@pub/@med/@dom/@lhi/doc uments/content/med_content_340495.pdf

40. Collagen – Masson’s Trichrome stain (TRI) [Internet]. Georgia (USA): The Internet Pathology Laboratory for Medical Education; date unknown [cited 2014 Feb 8]. Available from:

http://library.med.utah.edu/WebPath/HISTHTML/MANUALS/MASSONS.P DF

41. Helms SA, Azhar G, Zuo C, Theus SA, Bartke A, Wei JY. Smaller cardiac cell size and reduced extra-cellular collagen might be beneficial for hearts of Ames dwarf mice. Int J Biol Sci [Internet]. 2010 [cited 2014 Feb 8]; 6(5):475- 490. Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935670/?report=classic 42. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, et al.

Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest [Internet]. 2010

(7)

[cited 2014 Feb 8]; 120(10):3520-3529. Available from:

http://www.jci.org/articles/view/42028/pdf

43. Teori sederhana prosedur pemilihan uji hipotesis. In: Dahlan MS. Statistik untuk kedokteran dan kesehatan. Jakarta (Indonesia): Salemba Medika; 2011.

p. 1-29.

44. Statistik deskriptif. In: Dahlan MS. Statistik untuk kedokteran dan kesehatan.

Jakarta (Indonesia): Salemba Medika; 2011. p. 31-60.

45. Uji hipotesis komparatif variabel numerik lebih dari dua kelompok. In:

Dahlan MS. Statistik untuk kedokteran dan kesehatan. Jakarta (Indonesia):

Salemba Medika; 2011. p. 87-128.

46. Analisis kesintasan (Survival analysis). In: Sastroasmoro S, Ismael S. Dasar- dasar metodologi penelitian klinis. Jakarta (Indonesia): Sagung Seto; 2011, p.245-63.

47. Butler J. Primary prevention of heart failure. ISRN Cardiology. 2012 [cited 2014 July 13]. Available from

http://www.hindawi.com/journals/isrn.cardiology/2012/982417/

48. Kaliste-Korhonen E, Eskola S. Fighting in NIH/S male mice: consequence for behaviour in resident-intruder tests and physiological parameters. Lab Anim [Internet]. 2000 [cited 2014 Jul 14];34:189-98. Available from:

http://lan.sagepub.com/content/34/2/189.full.pdf

49. Van Loo PLP, Van Zutphen LFM, Baumans V. Male management: coping with aggression problems in male laboratory mice. Lab Anim [Internet]. 2003 [cited 2014 Jul 14]; 37:300-13. Available from:

http://lan.sagepub.com/content/37/4/300.full.pdf

50. Wu JC, Nasseri BA, Bloch KD, Picard MH, Scherrer-Crosbie M. Influence of sex on ventricular remodeling after myocardial infarction in mice. J Am Soc Echocardiogr [Internet]. 2003 [cited 2014 Jul 14]; 16(11):1158-62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14608287

(8)

51. Shioura KM, Geenen DL, Goldspink PH. Sex-related changes in cardiac function following myocardial infarction in mice. Am J Physiol Regul Integr Comp Physiol [Internet]. 2008 [cited 2014 Jul 2014];295(2):R528-34.

Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519934/

(9)

LAMPIRAN

Lampiran 1. Ethical Clearance

(10)

Lampiran 2. Izin Penelitian

(11)

Lampiran 3. Sertifikat Hewan Coba

(12)

Lampiran 4. Dokumentasi Penelitian

tempat pemeliharaan hewan coba

penyondean pemberian makan dan minum ad libitum

pengukuran panjang tibia pembedahan

pengukuran berat jantung

(13)

Lampiran 5. Luaran Analisis Program Statistik

BERAT BADAN HARI KE-1

Descriptives Berat Badan (pre)

N Mean

Std.

Deviation Std. Error

95% Confidence Interval for Mean

Minimum Maximum Lower Bound Upper Bound

ISO 11 27.18 1.537 .464 26.15 28.21 25 30

MET+ISO 11 27.91 2.982 .899 25.91 29.91 23 32

MET 11 28.82 2.359 .711 27.23 30.40 25 34

K 11 27.36 1.859 .560 26.11 28.61 25 31

Total 44 27.82 2.265 .341 27.13 28.51 23 34

Tests of Normality

Group

Kolmogorov-Smirnov^a Shapiro-Wilk

Statistic df Sig. Statistic df Sig.

Berat Badan (pre)

ISO .234 11 .096 .924 11 .351

MET+ISO .123 11 .200^* .953 11 .679

MET .197 11 .200^* .947 11 .602

K .184 11 .200^* .900 11 .187

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

(14)

Test of Homogeneity of Variances Berat Badan (pre)

Levene Statistic df1 df2 Sig.

1.861 3 40 .152

ANOVA Berat Badan (pre)

Sum of Squares df Mean Square F Sig.

Between Groups 17.818 3 5.939 1.172 .332

Within Groups 202.727 40 5.068

Total 220.545 43

(15)

BERAT BADAN HARI KE-28 Descriptives

Group Statistic

Std.

Error Berat Badan

(post)

ISO Mean 26.56 .766

Lower

Bound 24.79

Upper

Bound 28.32

5% Trimmed Mean 26.51

Median 27.00

Variance 5.278

Std. Deviation 2.297

Minimum 23

Maximum 31

Range 8

Interquartile Range 3

Skewness .386 .717

Kurtosis 1.172 1.400

MET+IS O

Mean 28.27 .935

Lower

Bound 26.19

(16)

Upper

Bound 30.36

Median 27.00

Variance 9.618

Minimum 25

Maximum 36

Range 11

Skewness 1.729 .661

MET Mean 26.18 1.016

Lower

Bound 23.92

Upper

Bound 28.45

Median 26.00

Variance 11.364

Minimum 22

(17)

Maximum 31

Range 9

Skewness -.096 .661

Kurtosis -1.706 1.279

K Mean 26.09 .780

Lower

Bound 24.35

Upper

Bound 27.83

Median 26.00

Variance 6.691

Minimum 22

Maximum 30

Range 8

Skewness .387 .661

Kurtosis -.646 1.279

(18)

Group

Berat Badan (post) ISO .201 9 .200^* .940 9 .581

MET+ISO .262 11 .033 .830 11 .023

MET .253 11 .048 .869 11 .076

K .241 11 .073 .912 11 .259

Group

Transformasi data BB (post) dengan fungsi LG10

ISO .196 9 .200^* .946 9 .643

MET+ISO .245 11 .063 .865 11 .067

MET .255 11 .045 .864 11 .065

K .224 11 .131 .924 11 .349

(19)

Test of Homogeneity of Variances BB (post) yang ditransformasi

1.394 3 38 .259

ANOVA

BB (post) yang ditransformasi

Between Groups .009 3 .003 1.375 .265

Within Groups .081 38 .002

Total .090 41

(20)

BERAT JANTUNG

Descriptives Berat Jantung (BJ)

N Mean

Std.

ISO 9 136.67 20.616 6.872 120.82 152.51 110 170

MET+ISO 11 129.09 23.856 7.193 113.06 145.12 100 170

MET 11 118.18 18.878 5.692 105.50 130.86 80 150

K 11 130.00 24.495 7.385 113.54 146.46 100 190

Total 42 128.10 22.332 3.446 121.14 135.05 80 190

Group

Statistic df Sig. Statistic Df Sig.

Berat Jantung (BJ) ISO .186 9 .200^* .927 9 .453

MET+ISO .212 11 .180 .894 11 .155

MET .189 11 .200^* .958 11 .741

K .251 11 .052 .858 11 .054

(21)

Test of Homogeneity of Variances Berat Jantung (BJ)

.187 3 38 .905

ANOVA Berat Jantung (BJ)

Between Groups 1793.074 3 597.691 1.218 .317

Within Groups 18654.545 38 490.909

Total 20447.619 41

(22)

RASIO BERAT JANTUNG/PANJANG TIBIA

Descriptives /PT N Mean

Std.

ISO 9 6.3489 1.00026 .33342 5.5800 7.1178 4.94 7.87

MET+ISO 11 5.8136 1.08955 .32851 5.0817 6.5456 4.45 7.72

MET 11 5.2864 .73816 .22256 4.7905 5.7823 3.80 6.43

K 11 5.9555 1.10354 .33273 5.2141 6.6968 4.73 8.67

Total 42 5.8274 1.02829 .15867 5.5069 6.1478 3.80 8.67

Group

/PT ISO .171 9 .200^* .947 9 .660

MET+ISO .200 11 .200^* .895 11 .160

MET .119 11 .200^* .974 11 .928

K .179 11 .200^* .870 11 .078

(23)

Test of Homogeneity of Variances /PT

.453 3 38 .717

ANOVA /PT

Between Groups 5.850 3 1.950 1.976 .134

Within Groups 37.502 38 .987

Total 43.352 41

(24)

RASIO BERAT JANTUNG/BERAT BADAN

Descriptives BJ/BB

N Mean

Std.

ISO 9 5.2000 .97848 .32616 4.4479 5.9521 3.55 6.52

MET+ISO 11 4.5645 .68238 .20575 4.1061 5.0230 3.70 6.07

MET 11 4.5518 .79004 .23820 4.0211 5.0826 3.64 5.91

K 11 5.0018 .93065 .28060 4.3766 5.6270 4.00 7.31

Total 42 4.8119 .86091 .13284 4.5436 5.0802 3.55 7.31

Group

BJ/BB ISO .197 9 .200^* .939 9 .566

MET+ISO .178 11 .200^* .934 11 .448

MET .204 11 .200^* .896 11 .164

K .185 11 .200^* .860 11 .058

(25)

Test of Homogeneity of Variances BJ/BB

.348 3 38 .791

ANOVA BJ/BB

Between Groups 3.169 3 1.056 1.475 .237

Total 30.388 41

(26)

LUAS FIBROSIS INTERSTISIAL JANTUNG

Descriptives

Group Statistic Std. Error

Luas Fibrosis Interstitial Jantung

ISO Mean 12169.18825 752.714126

Lower Bound 10433.42636 Upper Bound 13904.95013

Median 12521.64820

Variance 5099206.997

Minimum 8921.310

Maximum 14996.295

Range 6074.985

Interquartile Range 4369.786

Skewness -.021 .717

Kurtosis -1.620 1.400

MET+ISO Mean 5916.91975 931.513914

Median 4732.39740

(27)

Minimum 2291.576

Maximum 12594.507

Range 10302.931

Skewness 1.377 .661

MET Mean 7398.68602 766.694815

Median 7504.27020

Minimum 3327.990

Maximum 10740.997

Range 7413.007

Skewness -.096 .661

Kurtosis -1.338 1.279

K Mean 5614.57625 676.354174

(28)

Median 4828.96700

Minimum 3233.384

Maximum 9089.580

Range 5856.196

Skewness .792 .661

Kurtosis -1.072 1.279

(29)

Group

Statistic Df Sig. Statistic df Sig.

Luas Fibrosis Interstitial Jantung

ISO .186 9 .200^* .919 9 .385

MET+ISO .256 11 .043 .836 11 .028

MET .156 11 .200^* .930 11 .412

K .252 11 .050 .836 11 .028

Group

Statistic Df Sig. Statistic df Sig.

Luas fibrosis interstisial jantung yang ditransformasi dengan fungsi LG10

ISO .168 9 .200^* .923 9 .416

MET+ISO .190 11 .200^* .937 11 .489

MET .153 11 .200^* .921 11 .324

K .196 11 .200^* .894 11 .155

(30)

Test of Homogeneity of Variances Luas fibrosis interstisial yang ditransformasi

1.492 3 38 .232

ANOVA

Luas fibrosis interstisial yang ditransformasi

Between Groups .812 3 .271 9.996 .000

Total 1.840 41

(31)

Multiple Comparisons

Dependent Variable: Luas fibrosis interstisial yang ditransformasi LSD

(I) Group (J) Group

Mean Difference

(I-J) Std. Error Sig.

95% Confidence Interval Lower Bound Upper Bound

ISO MET+ISO .35323^* .07394 .000 .2035 .5029

MET .23577^* .07394 .003 .0861 .3855

K .35862^* .07394 .000 .2089 .5083

MET+ISO ISO -.35323^* .07394 .000 -.5029 -.2035

MET -.11746 .07015 .102 -.2595 .0246

K .00539 .07015 .939 -.1366 .1474

MET ISO -.23577^* .07394 .003 -.3855 -.0861

MET+ISO .11746 .07015 .102 -.0246 .2595

K .12284 .07015 .088 -.0192 .2649

K ISO -.35862^* .07394 .000 -.5083 -.2089

MET+ISO -.00539 .07015 .939 -.1474 .1366

MET -.12284 .07015 .088 -.2649 .0192

*. The mean difference is significant at the 0.05 level.

(32)

KESINTASAN

Case Processing Summary

Group Total N N of Events

Censored

N Percent

K 11 0 11 100.0%

ISO 11 2 9 81.8%

MET 11 0 11 100.0%

MET+ISO 11 0 11 100.0%

Overall 44 2 42 95.5%

(33)

Overall Comparisons

Chi-Square df Sig.

Log Rank (Mantel-Cox) 6.292 3 .098

Breslow (Generalized Wilcoxon) 6.286 3 .099

Tarone-Ware 6.289 3 .098

Test of equality of survival distributions for the different levels of Group.

(34)

Lampiran 6. Biodata mahasiswa Nama : Farah Firdausi

TTL : Semarang, 27 Oktober 1992 NIM : 22010110130144

Angkatan : 2010

Asal : Fakultas Kedokteran Universitas Diponegoro Alamat : Jln. Ngesrep Barat III/28D, Banyumanik, Semarang Telepon : 085718146155

Email : farahfirda2010@yahoo.com

Keanggotaan Organisasi

1. OSIS SMP Islam Al Azhar 14 Semarang (2006) 2. Komisi B FDI SMA Negeri 3 Semarang (2009) 3. Divisi Kaderisasi ROHIS SMA Negeri 3 Semarang (2009)

4. Staf Kesekretariatan BEM KU Undip (2011)

5. Staf Departemen Syi’ar Rohis Undip (2011-2012)

Pengalaman Penelitian

1. Pengaruh Metformin terhadap Fibrosis Interstisial Jantung dan Kesintasan pada Mencit Pasca-Infark Miokardium yang diinduski dengan Isoproterenol [Penelitian, 2014]

2. Yoghurt Kacang Tanah (Arachis hypogaea) sebagai Inovasi Pangan Sehat Anti-osteoporosis: Sebuah Studi Eksperimental pada Tikus Wistar Model Osteoporosis [Penelitian, 2014]

3. Prevalensi Infeksi Cacing Cambuk (Trichuris trichiura) dan Cacing Tambang (Necator americanus dan Ancylostoma duodenale) pada Ibu Hamil di Kota Semarang [Penelitian, 2013/2014]

Pengalaman Prestasi dan Mengikuti Lomba Karya Ilmiah

1. Inovasi Susu Sapi Terfortifikasi Koenzim Q10 menggunakan Mikroenkapsulasi Molekuler sebagai Terapi Ajuvan pada Penderita Gagal Jantung dengan Komorbiditas Depresi (Gagasan Tertulis, 2014)

2. Penerima Hibah Dana Pelaksanaan Penelitian PKM-P Tahun Anggaran 2014 oleh Direktorat Penelitian dan Pengabdian kepada Masyarakat Ditjen Pendidikan Tinggi Kementerian Pendidikan Nasional (2014)

3. Efek Pemberian Metformin terhadap Hipertrofi Miosit dan Fibrosis Interstisial Jantung pada Mencit Pasca-Infark Miokardium yang diinduksi dengan Isoproterenol (Proposal Penelitian, 2013)

(35)

4. Mycospray Berbasis Aspergillus niger entomopatogenik: Sebuah Inovasi Pengontrolan Resistensi dan Populasi Aedes aegypti dalam Upaya Pengendalian Dengue (Proposal Penelitian, 2013)

5. Juara 3 Lomba Proposal Penelitian dalam Research Project. Diselenggarakan oleh Bidang Riset Himpunan Mahasiswa Kedokteran Umum Universitas Diponegoro, Semarang (2013)

6. Juara 1 Lomba Proposal Penelitian Pekan Ilmiah Mahasiswa (PIM) Fakultas Kedokteran Universitas Diponegoro 2013. Diselenggarakan oleh Departemen Riset BEM FK KM Universitas Diponegoro, Semarang (2013)

9. Mahasiswa Berprestasi Fakultas Kedokteran Universitas Diponegoro. Dalam Rangka Dies Natalis ke-52 Fakultas Kedokteran Universitas Diponegoro (2013)

10. Juara 2 Cabang Sistem Digestif Indonesian Medical Olympiad (IMO) 2013.

Diselenggarakan oleh Ikatan Senat Mahasiswa Kedokteran Indonesia (ISMKI) & Fakultas Kedokteran Universitas Airlangga, Surabaya (2013) 11. Finalis 6 Besar Lomba Karya Tulis Ilmiah Gagasan Tertulis Temu Ilmiah

Nasional (Temilnas) 2013. Diselenggarakan oleh BAPIN-ISMKI dan Fakultas Kedokteran Universitas Padjadjaran, Bandung (2013)

12. Finalis Lomba Poster Ilmiah Temu Ilmiah Nasional (Temilnas) 2013.

Diselenggarakan oleh BAPIN-ISMKI dan Fakultas Kedokteran Universitas Padjadjaran, Bandung (2013)

13. Juara 1 Lomba Karya Tulis Ilmiah Gagasan Tertulis Nasional Scientific Fair 2013. Diselenggarakan oleh Himpunan Mahasiswa Kedokteran Umum Universitas Diponegoro, Semarang (2013)

14. 5^th Best Literature Review in Indonesia International (bio)Medical Students' Congress (INAMSC), Liga Medika 2013. Conducted by Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia (2013)

15. Bronze-Class Certificate for Excellent Performance in Multiple Choice Question Round of Siriraj International Medical Microbiology and Immunology Competition (SIMIC) 2013. Hosted by Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (2013)

16. Yoghurt Kacang Tanah (Arachis hypogaea) sebagai Inovasi Pangan Sehat Anti-osteoporosis: Sebuah Studi Eksperimental pada Tikus Wistar Model Osteoporosis (Proposal Penelitian, 2013)

(36)

17. Evidence Based Medicine: Tribendimidine sebagai Obat Alternatif Terbaru untuk Terapi Ascariasis (Literature Review & Poster Ilmiah, 2013)

18. Mycospray Berbasis Aspergillus niger Entomopatogenik: Sebuah Inovasi Pengontrolan Resistensi dan Populasi Aedes aegypti dalam Upaya Pengendalian Dengue (Gagasan Tertulis, 2013)

19. Suplementasi Quercetin pada Divine Kretek sebagai Upaya Preventif Karsinoma Paru (Gagasan Tertulis, 2013)

20. Curcumin in Curcuma longa as Inflammoregulator to Prevent Carcinogenesis of Colitis-associated Colorectal Cancer Promoted by Commensal pks⁺ Escherichia coli (Literature Review Paper, 2013)

21. Efek Pemberian Yoghurt Kacang Tanah (Arachis hypogaea) terhadap Kadar C-Telopeptida Serum, Kadar Alkali Fosfatase Serum dan Gambaran Histopatologi Tulang pada Tikus Ovariektomi Model Osteoporosis (Proposal Penelitian, 2012)

22. Potensi Idebenone untuk Optimalisasi Fungsi Mitokondria pada Penderita Leber Hereditary Optic Neuropathy (LHON) (Gagasan Tertulis, 2012)

23. Juara 1 Lomba Proposal Penelitian dalam Research Project. Diselenggarakan oleh Bidang Riset Himpunan Mahasiswa Kedokteran Umum Universitas Diponegoro (2012)

24. Finalis 10 Besar Scientific Paper Competition Sriwijaya Medical Science Olympiad (SMSO), Palembang (2012)